NANETS (North American Neuroendocrine Tumor Society) is one of the biggest NET conferences, bringing together NET Specialists from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field of Neuroendocrine Neoplasms (Tumors and Carcinomas). This is fairly complex stuff but much of it will be familiar to many. I’ve filtered out several outputs from the conference which I think are both relevant and topical to patients. The list is below allowing you to easily peruse and read further via linkages if you need to read more. Remember, some of these are extracts so do not contain all the details of the research or study – although some of the linkages will take you to in-depth information if that’s your bag. Where applicable, I’ve also linked to some of my blog posts to add context and detail in patient speak. The list comprises articles which were published in medical news media and for which I received alerts. It does not comprise the entire schedule of NANETS 2017. I may add more to the list if other relevant and interesting articles are published downstream.
Some of the output from the conference is in ‘study form’ and has not yet been published as peer-reviewed data (important notice to readers).
|NANETS to Bring All Specialties in the NETs Community Together for 10th Annual Symposium
Interview with Michael Soulen MD. Nice introduction.
|Location of Neuroendocrine Tumors in the Small Bowel Does Not Affect Survival
|Diagnosing and Treating NET-Related Diarrhea
|Incorporated into my Diarrhea article – https://goo.gl/PwsXmX
|Emerging Therapies, Biologic Discoveries, and Improved QoL on Horizon for NETs
|Retrospective Database Analysis Studies Somatostatin Analog Usage in NETs
|Regional Lymph Node Involvement and Outcomes in Appendiceal Neuroendocrine Tumors: A SEER Database Analysis.
|Personalizing Therapy With PRRT and Improving Imaging With SSTR-PET Brings Novel Options to NETs Landscape
(new term SSTR-PET generically meaning any PET scan using somatostatin receptors), e.g. Ga68 etc.
|PFS and OS After Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lu[Dota⁰,Tyr³] octreotate in Patients with GastroEnteroPancreatic or Bronchial NeuroEndocrine Tumours (GEP-NETs) – The Rotterdam Cohort
|Molecular Classification of Neuroendocrine Tumors: Clinical Experience with the 92-gene Assay in >24,000 Cases
|Neuroendocrine Tumors: A Patient Survey
“Regarding their biggest challenges, patients reported fatigue as their biggest challenge followed by diarrhea, sleep disturbances, and pain.”
|Phase III Trial Needed to Confirm Clinical Benefit of Cabozantinib in NETs
|Incorporated into my Cabozantinib article – https://goo.gl/mR2yFT
|QOL Improvements in NETTER-1 Phase III Trial in Patients with Progressive Midgut Neuroendocrine Tumors. (I think this is well-known but no harm in repeating it!)
The full link to all poster abstracts for NANETS 2017 can be found here
Thanks for reading
Hey Guys, I’m also active on Facebook. Like my page for even more news.
My Diagnosis and Treatment History
Most Popular Posts
Sign up for my twitter newsletter
Check out my Podcast (click and press play)
Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
2 thoughts on “Round up of NANETS 2017 – Let’s talk about NETs #NANETS2017”